Press Releases

Date	Title and Summary	Additional Formats
Toggle Summary May 19, 2016	Evoke Enters Exclusive Commercial Supply Agreement for Active Pharmaceutical Ingredient in EVK-001 SOLANA BEACH, Calif., May 19, 2016 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), today announced that it has signed an exclusive commercial supply agreement with COSMA S.p.A. for the active pharmaceutical ingredient (API) in its product candidate EVK-001.	View HTML Evoke Enters Exclusive Commercial Supply Agreement for Active Pharmaceutical Ingredient in EVK-001 16.1 KB
Toggle Summary May 11, 2016	Evoke Pharma Reports First Quarter 2016 Results SOLANA BEACH, Calif., May 11, 2016 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced its financial results for the first quarter ended March 31, 2016.	View HTML Evoke Pharma Reports First Quarter 2016 Results 25 KB
Toggle Summary May 05, 2016	Evoke Pharma Schedules Webcast and Conference Call for First Quarter 2016 Financial Results SOLANA BEACH, Calif., May 05, 2016 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that it will issue its financial results for the first quarter 2016 on Wednesday, May 11, 2016, after	View HTML Evoke Pharma Schedules Webcast and Conference Call for First Quarter 2016 Financial Results 15.6 KB
Toggle Summary May 03, 2016	Evoke Announces Timing of Phase 3 Results from its Recently Fully Enrolled Pivotal Clinical Trial of EVK-001 SOLANA BEACH, Calif., May 03, 2016 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK) today announced that it expects to provide top line data results from its pivotal Phase 3 clinical trial of EVK-001 in women with symptoms associated with diabetic gastroparesis early in the third quarter of	View HTML Evoke Announces Timing of Phase 3 Results from its Recently Fully Enrolled Pivotal Clinical Trial of EVK-001 15.6 KB
Toggle Summary Apr 25, 2016	Evoke Successfully Completes Phase 3 Clinical Trial Enrollment of EVK-001 in Women with Symptoms Associated with Diabetic Gastroparesis SOLANA BEACH, Calif., April 25, 2016 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), today announced that it has successfully completed patient enrollment in its pivotal Phase 3 clinical trial of EVK-001, its patented nasal delivery formulation of metoclopramide for the relief of symptoms	View HTML Evoke Successfully Completes Phase 3 Clinical Trial Enrollment of EVK-001 in Women with Symptoms Associated with Diabetic Gastroparesis 17.9 KB
Toggle Summary Mar 10, 2016	Evoke Pharma Reports Fourth Quarter and Year End 2015 Results Provides Outlook for Completing Phase 3 Clinical Trial and Upcoming NDA Submission	View HTML Evoke Pharma Reports Fourth Quarter and Year End 2015 Results 28.5 KB
Toggle Summary Mar 04, 2016	Evoke Pharma Schedules Webcast and Conference Call for Fourth Quarter and Year End 2015 Financial Results SOLANA BEACH, Calif., March 04, 2016 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that it will issue its financial results for the fourth quarter and full year 2015 on Thursday,	View HTML Evoke Pharma Schedules Webcast and Conference Call for Fourth Quarter and Year End 2015 Financial Results 15.7 KB
Toggle Summary Mar 03, 2016	Evoke Accelerates New Drug Application Process by Engaging Regulatory Experts NDA Preparation Initiates as EVK-001 Nears Phase 3 Study Completion	View HTML Evoke Accelerates New Drug Application Process by Engaging Regulatory Experts 15.9 KB
Toggle Summary Mar 01, 2016	Evoke Nears Completion of Phase 3 Clinical Trial Enrollment and Secures Extension to Credit Facility 186 of 200 Subjects Enrolled in Phase 3 Clinical Trial of EVK-001	View HTML Evoke Nears Completion of Phase 3 Clinical Trial Enrollment and Secures Extension to Credit Facility 16.9 KB
Toggle Summary Feb 17, 2016	Evoke Pharma to Present Results From Successful Thorough ECG (TQT) Study of EVK-001 at Digestive Disease Week 2016 Clinical Data Support Cardiac Safety of EVK-001	View HTML Evoke Pharma to Present Results From Successful Thorough ECG (TQT) Study of EVK-001 at Digestive Disease Week 2016 16.2 KB